CARMAT 
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 2.8M 3.02M 4.13M | Sales 2024 * | 15.45M 16.67M 22.8M | Capitalization | 104M 112M 154M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -57.2M -78.21M | Net income 2024 * | -38M -41.01M -56.08M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.57M 73.24M | Net Debt 2024 * | 68.9M 74.36M 102M | EV / Sales 2024 * | 11.2 x |
| P/E ratio 2023 |
-3.09
x | P/E ratio 2024 * |
-3.16
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| +10.39% | 126B | |
| +2.52% | 8.97B | |
| +38.96% | 5.56B | |
| -17.50% | 4.99B | |
| +8.36% | 3.44B | |
| -8.84% | 2.8B | |
| -7.52% | 2.18B | |
| -3.00% | 2.16B | |
| -21.88% | 1.82B |
